New combo tackles Hard-to-Treat leukemia
NCT ID NCT05024552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a combination of two drugs, vyxeos and gilteritinib, for adults whose FLT3-mutated acute myeloid leukemia has come back or not responded to prior treatment. The goal is to find the safest dose and see how many patients achieve remission. Participants who respond may continue with more treatment or a stem cell transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to outsmart aggressive leukemia
- New combo therapy targets Hard-to-Cure leukemia
- New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
- New combo aims to outdo standard chemo for FLT3-Mutated leukemia
- New drug cocktail may replace bone marrow transplant for some leukemia patients
- New Two-Step transplant shows promise for tough blood cancers